PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study identifies how ovarian cancer protects itself, paves way for improved immunotherapy approach

Eczema-linked protein helps cancer survive, suggesting potential for skin drug-based treatment

Study identifies how ovarian cancer protects itself, paves way for improved immunotherapy approach
2024-10-30
(Press-News.org) New York, NY [October 30, 2024]—Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance.

The study, published in the October 30 online issue of Cell [DOI: 10.1016/j.cell.2024.10.006], used a cutting-edge spatial genomics technology and preclinical animal models, with tumor specimens from ovarian cancer patients further validating the findings.

The researchers found that ovarian cancer cells produce a molecule called Interleukin-4 (IL-4), which is typically associated with asthma and the skin condition eczema, also known as atopic dermatitis. The study went on to find that the cancer cells used IL-4 to create a protective environment that kept away killer immune cells, making the tumors resistant to immunotherapy. A drug, dupilumab, which blocks IL-4’s activity, has been approved by the Food and Drug Administration (FDA) and is already used to treat asthma and eczema. This new study suggests dupilumab or similar drugs could be repurposed to enhance immunotherapy for ovarian cancer.

Ovarian cancer is one of the most deadly cancers; 50 percent of patients die within five years of diagnosis. While immunotherapy drugs such as pembrolizumab, which target the PD-1 molecule, have demonstrated efficacy in treating melanoma and lung cancer, they have not significantly improved survival rates in ovarian cancer. This is partly because ovarian tumors have fewer mutations, making them harder for the immune system to recognize. Additionally, research suggests that these tumors may resist immunotherapy by creating barriers that prevent immune cells from infiltrating their borders. The critical question, say the investigators, has been: how do tumors establish these protective environments?

To address this question, the research team, led by Alessia Baccarini, PhD, Assistant Professor of Immunology and Immunotherapy, and Brian D. Brown, PhD, Director of the Icahn Genomics Institute at Icahn Mount Sinai, used a novel genomics technology known as Perturb-map. Perturb-map enhances traditional gene-editing CRISPR screening—where hundreds of genes are simultaneously “perturbed”—by incorporating state-of-the-art spatial imaging. This enables each gene’s role in controlling the tumor environment to be elucidated. Their experiments revealed that removing the IL-4 gene from ovarian cancer cells rendered the tumors susceptible to anti-PD-1 therapy.

“Surprisingly, the IL-4-deficient cancer cells were eliminated by the immune system even when mixed within tumors containing IL-4-producing cancer cells, a phenomenon known as intratumoral heterogeneity, which also contributes to drug resistance in cancer,” says Dr. Brown, who is Mount Sinai Professor of Genetic Engineering and senior author of the study.

The researchers then tested a combination of anti-PD-1 and IL-4 receptor-blocking drugs in mice with aggressive metastatic ovarian cancer and found that this combination treatment significantly extended their survival.

Additional preclinical studies demonstrated that ovarian cancer uses IL-4 to program macrophages, a type of immune cell, into protectors of the cancer cells. The IL-4-programmed macrophages prevented T cells from killing the cancer cells. However, when IL-4 was blocked, the local environment surrounding the cancer cells changed, and this left the malignant cells susceptible to being eliminated by the immune system.

To further validate their findings, the team examined specimens from human ovarian tumor resections and saw that the patients’ cancer cells also produced IL-4. Moreover, analysis of single-cell RNA sequencing data from patient tumors—which examines how genes are expressed in cells—revealed that the macrophages displayed a strong IL-4 signature, suggesting that IL-4 is playing a similar role in human ovarian cancer and may be one of the reasons patients have not benefited from immunotherapy.

“Ovarian cancer has almost been written off as non-responsive to existing immunotherapy, so it was quite stunning to us that by just blocking this one molecule, IL-4, and altering the tumor’s microenvironment, we could make these difficult-to-treat tumors more treatable,” adds Dr. Brown. “This is further evidence that targeting the tumor’s neighborhood, not just the cancer cells, can be beneficial.”

While these findings are encouraging, the investigators stress that clinical trials are essential to determine whether targeting IL-4 can enhance patient outcomes. Given that dupilumab is already FDA-approved for asthma and eczema, there is potential for swift clinical testing alongside immunotherapy to enhance survival in ovarian cancer patients. Thomas Marron, MD, PhD, Director of the Early Phase Trial Unit at Mount Sinai and a colleague of Drs. Brown and Baccarini, has already been running a clinical study to test whether dupilumab can improve anti-PD-1 immunotherapy in patients with lung cancer, and several patients have shown beneficial responses.

“Ovarian cancer is a disease that’s so hard to catch early and once diagnosed, it’s often too late. I am excited that these findings may make a difference in patients’ lives. The IL-4 pathway is already targeted for diseases like eczema, and I am hopeful that if we target it in ovarian cancer, we can help women facing this terrible disease,” says Dr. Baccarini.

The paper is titled “Ovarian cancer-derived IL-4 promotes immunotherapy resistance.”

To view details on the remaining authors and competing interests, see: [DOI: 10.1016/j.cell.2024.10.006].

The work was supported by NIH awards R01AT011326, R01CA254104, R01CA257195, U2C-CA233262, U01CA284207, U01CA282114, and funding from the Cancer Research Institute, the Feldman Foundation, the Applebaum Foundation, and Ludwig Cancer Research.

-####-

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.  

Ranked 13th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 44 academic departments and 36 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases. 

Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System. 

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.

Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

------------------------------------------------------- 

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

 

 

 

 

 

 

 

 

 

 

 

END


[Attachments] See images for this press release:
Study identifies how ovarian cancer protects itself, paves way for improved immunotherapy approach Study identifies how ovarian cancer protects itself, paves way for improved immunotherapy approach 2

ELSE PRESS RELEASES FROM THIS DATE:

State policies regulating law enforcement access to prescription drug monitoring program testosterone prescription data

2024-10-30
About The Study: This study found that testosterone prescription data through prescription drug monitoring programs was accessible to law enforcement without basic safeguards (such as a warrant or subpoena) in nearly half of states. The ease of access to this sensitive medical information raises privacy, care quality, and civil liberties concerns, especially amid the proliferation of gender-affirming care bans. Corresponding Author: To contact the corresponding author, Katie McCreedy, MPH, email mccreedy.k@northeastern.edu. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jama.2024.20035) Editor’s ...

Validation of the Kansas City Cardiomyopathy Questionnaire in patients with tricuspid regurgitation

2024-10-30
About The Study: In this cohort study, the Kansas City Cardiomyopathy Questionnaire (KCCQ) had strong psychometric properties in patients with severe tricuspid regurgitation, including reliability, responsiveness, and validity. These data support use of the KCCQ in patients with severe tricuspid regurgitation as a measure of their symptoms, function, and quality of life and also for assessing the impact of interventions, such as transcatheter tricuspid valve intervention, in rigorously controlled trials.  Corresponding Author: To contact the corresponding ...

New study shows combination therapy slows cognitive decline in at-risk populations

2024-10-30
An important new study led by the Centre for Addiction and Mental Health (CAMH), and with partnership across several Toronto Dementia Research Alliance (TDRA) sites— Baycrest, Sunnybrook Health Science Centre, Unity Health Toronto, and University Health Network— has demonstrated that a combination therapy can slow cognitive decline in older adults at risk for dementia. The study was published today in JAMA Psychiatry: "Slowing cognitive decline in major depressive disorder and mild cognitive ...

Slowing cognitive decline in major depressive disorder and mild cognitive impairment

2024-10-30
About The Study: This study showed that cognitive remediation and transcranial direct current stimulation, both targeting the prefrontal cortex, is efficacious in slowing cognitive decline in older adults at risk of cognitive decline, particularly those with remitted major depressive disorder (with or without mild cognitive impairment) and in those at low genetic risk for Alzheimer disease.  Corresponding Author: To contact the corresponding authors, email Benoit H. Mulsant, MD, MS, (benoit.mulsant@utoronto.ca) and Tarek K. Rajji, MD, (tarek.rajji@utsouthwestern.edu) To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (10.1001/jamapsychiatry.2024.3241) Editor’s ...

Autism diagnosis among US children and adults

2024-10-30
About The Study: In this cross-sectional study of children and adults in the U.S., autism spectrum disorder diagnosis rates increased substantially between 2011 and 2022, particularly among young adults, female children and adults, and children from some racial or ethnic minority groups. Diagnosis prevalence trends generated using health system data can inform the allocation of resources to meet the service needs of this growing, medically complex population. Corresponding Author: To contact the corresponding author, Luke P. Grosvenor, PhD, email luke.p.grosvenor@kp.org. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamanetworkopen.2024.42218) Editor’s ...

Researchers identify “sweet spot” for safe surgery after heart attack

2024-10-30
After a heart attack, aging adults face double or triple the risk of life-threatening complications – like a debilitating stroke or another heart attack – when they move forward with elective noncardiac surgeries too soon, according to new University of Rochester research published in JAMA Surgery. A deep dive into the Medicare database of 5.2 million surgeries from 2017 to 2020 for patients 67 and older suggests delaying surgery for three to six months following a heart attack, known as a non-ST-segmented elevation myocardial infarction (NSTEMI). Researchers aim to identify the “sweet spot” for safely scheduling additional surgical procedures ...

Children’s Hospital of Philadelphia researchers identify disparities in healthcare system point of entry for pediatric concussion care

2024-10-30
Philadelphia, October 30, 2024 – Researchers from Children’s Hospital of Philadelphia (CHOP) found that non-Hispanic Black children and those with public insurance and lower Child Opportunity Index (COI) scores were much more likely to seek care for concussions in the emergency department than in primary care or specialty care settings. The findings underscore the need to ensure emergency medicine physicians have specific training and education for diagnosing and managing pediatric concussion and suggest that establishing up-to-date community-level resources could improve care equity for children with possible concussion. The findings were published today by JAMA Network ...

Solar-powered animal cells

Solar-powered animal cells
2024-10-30
Energy-making chloroplasts from algae have been inserted into hamster cells, enabling the cells to photosynthesize light, according to new research in Japan. It was previously thought that combining chloroplasts (chlorophyll containing structures in the cells of plants and algae) with animal cells was not possible, and that the chloroplasts would not survive or function. However, results showed that photosynthetic action continued for at least two days. This technique could be useful for artificial tissue engineering. ...

ACS research finds lack of health insurance coverage contributes to racial and ethnic disparities in advanced-stage diagnosis of multiple cancers

ACS research finds lack of health insurance coverage contributes to racial and ethnic disparities in advanced-stage diagnosis of multiple cancers
2024-10-30
A new, large study led by American Cancer Society (ACS) researchers found that lack of health insurance coverage accounts for a significant proportion of racial and ethnic disparities in advanced-stage diagnosis of multiple cancers. The findings are published today in the Journal of the National Cancer Institute (JNCI). “Health insurance coverage is a key determinant of access to high-quality healthcare across the cancer continuum from prevention to early detection, treatment, and survivorship in the United States,” said Dr. Parichoy Pal Choudhury, Principal Scientist, Biostatistics at the American ...

Exploring the cost and feasibility of battery-electric ships

2024-10-30
— By Jessica Scully Retrofitting a portion of the US shipping fleet from internal combustion engines to battery-electric systems could significantly reduce greenhouse gas emissions and be largely cost effective by 2035, according to a new study from Berkeley Lab researchers recently published in Nature Energy. Shipping represents 3% of total US greenhouse gas emissions from transportation, making it an important target for decarbonization. But electrifying ships is more challenging than ...

LAST 30 PRESS RELEASES:

Mathematical model illuminates how environment impacts life choices of salmon

Houston Methodist researchers shed light on increased rates of severe human infections caused by Streptococcus subspecies

Auburn University hosts 62nd Hands-On Workshop on Computational Biophysics, featuring the new VMD 2.0

The Salton Sea — an area rich with lithium — is a hot spot for child respiratory issues

University of Maryland-YouGov poll: Alsobrooks dominates Hogan, amendment to state constitution garners broad support

Exposure to particular sources of air pollution is harmful to children’s learning and memory, a USC study shows

Change of ownership in home health agencies may lead to increased Medicare spending and reduced staffing levels, according to UTHealth Houston research

More resources needed to protect birds in Germany

Mission to International Space Station launches research on brain organoids, heart muscle atrophy, and cold welding

nTIDE November 2024 Jobs Report: Disability employment remains near historic highs over past 18 months

Researchers aim to streamline cancer detection with new method for liquid biopsies

New Huntington’s treatment prevents protein aggregation

Bee gene specifies collective behavior

Jennifer Bickel, M.D., named MD Anderson Vice President and Chief Wellness Officer

Evolutionary paths vastly differ for birds, bats

Political pros no better than public in predicting which messages persuade

Investment in pediatric emergency care could save more than 2,100 young lives annually

The dynamic core of black holes

Improving energy production by boosting singlet fission process

Smoking cessation and incident cardiovascular disease

Cannabis use during early pregnancy following recreational cannabis legalization

Research shows Cleveland Clinic’s therapeutic virtual yoga program can be effective for chronic low back pain

Closing in on Parkinson’s Disease proteins in extracellular vesicles in the blood

Regional and global experts convene in Accra, Ghana to update cancer treatment guidelines for Sub-Saharan Africa

China University of Geosciences (Beijing) unveils clues to an enigmatic geological process

Fueling greener aviation with hydrogen

Education, occupation, and wealth affect the risk of cognitive impairment

Revealing causal links in complex systems

Alzheimer disease as a clinical-biological construct— an international working group recommendation

Press registration now open for the EULAR 2025 Congress in Barcelona

[Press-News.org] Study identifies how ovarian cancer protects itself, paves way for improved immunotherapy approach
Eczema-linked protein helps cancer survive, suggesting potential for skin drug-based treatment